Turoctocog alfa pegol
In February 2019, the FDA approved antihemophilic factor (recombinant), glycopegylated-exei (turoctocog alfa pegol) (Esperoct) for the treatment of hemophilia A. Turoctocog alfa pegol was approved for medical use in the European Union in June 2019. References
External links
"Turoctocog alfa". Drug Information Portal. U.S. National Library of Medicine. "Turoctocog alfa pegol". Drug Information Portal. U.S. National Library of Medicine.
Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women. It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet. The medication was approved in the United States in 2005. It is marketed widely throughout the world. See also
Estetrol/drospirenone
Ethinylestradiol/drospirenone
Ethinylestradiol/drospirenone/levomefolic acid
Ethinylestradiol/drospirenone/prasterone
List of combined sex-hormonal preparations § Estrogens and progestogens

References
External links
Angeliq (estradiol/drospirenone) FDA Label
Estradiol/drospirenone (Angeliq) - AdisInsight